Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 7, 1998, Pages 2244-2254

  Dave Sharma, Swati ^a   Wilson, Robert C ^a   Harbison, Madeleine D ^a   Newfield, Ron ^a   Azar, Maryam Razzaghy ^a   Krozowski, Zygmunt S ^a   Funder, John W ^a   Shackleton, Cedric H L ^a   Bradlow, H Leon ^a   Wei, J I Qing ^a   Hertecant, Jos ^a   Moran, Antoinette ^a   Neiberger, Richard E ^a   Balfe, J Williamson ^a   Fattah, Abduhl ^a   Daneman, Denis ^a   Akkurt, H Ilker ^a   De Santis, Carlo ^a   New, Maria I ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; HYDROCORTISONE; TETRAHYDROCORTISOL;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENOTYPE; GROWTH DISORDER; HEART INJURY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOALDOSTERONISM; HYPOKALEMIC ALKALOSIS; KIDNEY INJURY; PHENOTYPE; PRIORITY JOURNAL; RETINOPATHY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, RECESSIVE; GENOTYPE; GROWTH DISORDERS; HUMANS; HYDROCORTISONE; HYPERTENSION; INFANT; MALE; METABOLIC DISEASES; MINERALOCORTICOIDS; MUTATION; PEDIGREE; PHENOTYPE; SPIRONOLACTONE; SYNDROME; TREATMENT OUTCOME;

EID: 7844240856     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.7.2244     Document Type: Article

References (61)

1. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. 1977 Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab. 44:924-933.
2. Werder EA, Zachmann M, Vollmin JA, Veyrat R, Trader A. 1974 Unusual steroid excretion in a child with low-renin hypertension. Res Steroids. 6:385-389.
3. Ulick S, Levine LS, Gunczler P, et al. 1979 A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab. 49:757-764.
4. Shackleton CH, Rodriguez J, Arteaga E, Lopez JM, Winter JS. 1985 Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf). 22:701-712.
5. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest. 82:340-349.
6. Batista MC, Mendonca BB, Kater CE, et al. 1986 Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome. J Pediatr. 109:989-993.
7. Monder C, Shackleton CH, Bradlow HL, et al. 1986 The syndrome of apparent mineralocorticoid excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab. 63:550-557.
8. Wilson RC, Krozowski ZS, Li K, et al. 1995 A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 80:2263-2266.
9. Wilson RC, Harbison MD, Krozowski ZS, et al. 1995 Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 80:3145-3150.
10. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. 1995 Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet. 10:394-399.
11. Kitanaka S, Tanae A, Hibi I. 1996 Apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Clin Endocrinol (Oxf). 44:353-359.
12. Sann L, Revol A, Zachmann M, Legrand JC, Bethenod M. 1976 Unusual low plasma renin hypertension in a child. J Clin Endocrinol Metab. 43:265-271.
13. Shackleton CH, Honour JW, Dillon MJ, Chantier C, Jones RW. 1980 Hypertension in a four-year-old child: gas Chromatographic and mass spectrometric evidence for deficient hepatic metabolism of steroids. J Clin Endocrinol Metab. 50:786-802.
14. Honour JW, Dillon MJ, Levin M, Shah V. 1983 Fatal, low renin hypertension associated with a disturbance of cortisol metabolism. Arch Dis Child. 58:1018-1020.
15. Milford DV, Shackleton CHL, Stewart PM. 1995 Mineralocorticoid hypertension and congenital deficiency of 11β-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess. Clin Endocrinol (Oxf). 43:241-246.
16. Muller-Berghaus J, Homoki J, Michalk DV, Querfeld U. 1996 Diagnosis and treatment of a child with the syndrome of apparent mineralocorticoid excess type 1. Acta Paediatr. 85:111-113.
17. Fiselier TJ, Otten BJ, Monnens LA, Honour JW, van Munster PJ. 1982 Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child. Horm Res. 16:107-114.
18. Harinck HI, van Brummelen P, Van Seters AP, Moolenaar AJ. 1984 Apparent mineralocorticoid excess and deficient 11 beta-oxidation of cortisol in a young female. Clin Endocrinol (Oxf). 21:505-514.
19. Winter JSD, McKenzie JK. 1977 A syndrome of low-renin hypertension in children. In: New MI, Levine S, eds. Juvenile hypertension. New York: Raven Press; 123-132.
20. Nikkila H, Tannin GM, New MI, et al. 1993 Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab. 77:687-691.
21. Gourmelen M, Saint-Jacques I, Morineau G, Soliman H, Julien R, Fiet J. 1996 11β-Hydroxysteroid dehydrogenase deficit: a rare cause of arterial hypertension. Diagnosis and therapeutic approach in two young brothers. Eur J Endocrinol. 135:238-244.
22. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie JA, Sheppard MC. 1996 Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydorgenase type 2 gene. Lancet. 347:88-91.
23. Kitanaka S, Katsumata N, Tanae A, et al. 1997 A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 82:4054-4058.
24. Li S, Li KXZ, Marui S, et al. 1997 Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens. 15:1397-1402.
25. Ulick S, Ramirez LC, New MI. 1977 An abnormality in steroid reductive metabolism in a hypertensive syndrome. J Clin Endocrinol Metab. 44:799-802.
26. Oberfield SE, Levine LS, Carey RM, Greig F, Ulick S, New MI. 1983 Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab. 56:332-339.
27. Lan NC, Matulich DT, Stockigt JR, et al. 1980 Radioreceptor assay of plasma mineralocorticoid activity. Role of aldosterone, cortisol, and deoxycorticosterone in various mineralocorticoid-excess states. Circ Res. 46:194-1100.
28. Naray-Fejes-Toth A, Fejes-Toth G. 1994 11β-Hydroxysteroid dehydrogenase in renal collecting duct cells. Steroids. 59:105-110.
29. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. 1994 Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17.
30. Krozowski Z, Ma Guire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. 1995 Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 80:2203-2209.
31. Krozowski Z, Albiston AL, Obeyesekere VR, Andrews RK, Smith RE. 1995 The human 11 beta-hydroxysteroid dehydrogenase type II enzyme: comparisons with other species and localization to the distal nephron. J Steroid Biochem Mol Biol. 55:457-464.
32. Zhetcho K, Walker PD, Reeves WB. 1996 Immunolocalization of NAD-dependent 11 beta-hydroxysteroid dehydrogenase in human kidney and colon. Kidney Int. 49:271-281.
33. Obeyesekere VR, Ferrari P, Andrews RK, et al. 1995 The R337C mutation generates a high Km 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 80:3381-3383.
34. Ferrari P, Obeyesekere VR, Li K, et al. 1996 Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol. 119:21-24.
35. DiMartino-Nardi J, Stoner E, Martin K, Balfe JW, Jose PA, New MI. 1987 New findings in apparent mineralocorticoid excess. Clin Endocrinol (Oxf). 27:49-62.
36. Abraham GE, Corrales PC, Teller RC. 1972 Radioimmunoassay of plasma 17-hydroxyprogesterone. Anal Lett. 5:915.
37. Abraham GE, Manlimos FS, Solis M, Wickman AC. 1975 Combined radioimmunoassay of four steroids in one ml of plasma. II. Androgens. Clin Biochem. 8:374-378.
38. Korth-Schutz S, Levine LS, New MI. 1976 Serum androgens in normal prepubertal and pubertal children and in children with precocious adrenarche. J Clin Endocrinol Metab. 42:117-124.
39. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. 1977 Microfilter paper method for 17-hydroxyprogesterone radioimmunassay. J Clin Endocrinol Metab. 45:1003-1008.
40. Rauh W, Levine LS, Gottesdiener K, et al. 1979 Adrenocortical function, electrolyte metabolism, and blood pressure during prolonged adrenocorticotropin infusion in juvenile hypertension. J Clin Endocrinol Metab. 49:52-57.
41. Sonino N, Chow D, Levine LS, New MI. 1981 Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Clin Endocrinol (Oxf). 14:31-39.
42. Sealey JE, Campbell G, Preibisz JJ. 1990 Renin, aldosterone, peripheral vein, renal vein, and urinary assays. In: Laragh JH, Brenner BM, eds. Hypertension pathophysiology: diagnosis and managment. New York: Raven Press; 1443-1459.
43. Shackleton CHL. 1993 Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol. 45:127-140.
44. Hellman L, Nakada F, Zumoff B, Fukushima D, Bradlow HL, Gallagher TF. 1971 Renal capture and oxidation of cortisol in man. J Clin Endocrinol Metab. 33:52-62.
45. Wilson RC, Wei JQ, Cheng KC, Mercado AB, New MI. 1995 Rapid DNA analysis by allele-specific PCR for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab. 80:1635-1640.
46. Coleman JP, White WB, Lijewski M, Hylemon PB. 1988 Nucleotide sequence and regulation of a gene involved in bile acid 7-dehydroxylation by Eubacterium sp. strain VPI 12708. J Bacteriol. 170:2070-2077.
47. Ghosh D, Weeks CM, Grochulski P, et al. 1991 Three-dimensional structure of holo 3 alpha,20 beta-hydroxysteroid dehydrogenase: a member of a short-chain dehydrogenase family. Proc Natl Acad Sci USA. 88:10064-10068.
48. Krozowski Z. 1992 11β-Hydroxysteroid dehydrogenase and the short-chain alcohol dehydrogenase (SCAD) superfamily. Mol Cell Endocrinol. 84:C25-C31.
49. Chou PY, Fasman GD. 1974 Prediction of protein conformation. Biochemistry. 13:222-245.
50. Chou PY, Fasman GD. 1974 Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. Biochemistry. 13:211-222.
51. Chou PY, Fasman GD. 1978 Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 47:45-148.
52. Chou PY, Fasman GD. 1978 Empirical predictions of protein conformation. Annu Rev Biochem. 47:251-276.
53. Brown RW, Chapman KE, Edwards CR, Seckl JR. 1993 Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology. 132:2614-2621.
54. Brown RW, Chapman KE, Kotelevtsev Y, et al. 1996 Cloning and production of antisera to human placental 11β-hydroxysteroid dehydrogenase type 2. Biochem J. 313:1007-1017.
55. Benediktsson R, Calder AA, Edwards CRW, Seckl JR. 1997 Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf). 46:161-166.
56. Stewart PM, Rogerson FM, Mason JI. 1995 Type 2 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab. 80:885-890.
57. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR. 1996 11 beta-hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects. Steroids. 61:263-269.
58. Benediktsson R, Noble J, Calder AA, Edwards CRW, Seckl JR. 1995 11β-Hydroxysteroid dehydrogenase activity in intact dually-perfused fresh human placenta predicts birth weight. J Endocrinol. 144(Suppl):166.
59. Gomez-Sanchez EP, et al. 1995 The modulation of central control of blood pressure. Steroids. 60:69-72.
60. Roberts AJ, Keith LD. 1995 Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Psychoneuroendocrinology. 20:891-902.
61. Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE. 1996 Mineralocorticoids, salt and high blood pressure. Steroids. 61:184-188.